healthcare-thumbnail.png

Liver Cancer Market Research Report

Published: 2025 - January

Report Code: VMR-8530

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

Liver Cancer Market Analysis 

The Liver Cancer Market represents a dynamic and rapidly advancing segment of oncology, addressing primary liver malignancies such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and rare variants like angiosarcoma. The market is shaped by breakthroughs in immunotherapies, targeted therapies, and innovative combination approaches to address unmet clinical needs in early, intermediate, and advanced stages of liver cancer. Precision medicine and novel treatment modalities are revolutionizing patient care, aiming to extend survival and improve quality of life.

Disruptive Impact and Opportunities:

The market is undergoing significant disruption, with novel mechanisms targeting immune checkpoint pathways, oncogenic signaling, and epigenetic regulation. These innovations introduce New therapeutic paradigms with improved efficacy and specificity, making advanced treatments Easier to administer via innovative delivery platforms. Moreover, the introduction of minimally invasive therapies enhances patient Safety, reducing side effects. Given the rising global burden of liver cancer and increasing investment in R&D, the market presents Big growth opportunities for stakeholders.

Liver Cancer Market Segmentation - Emerging Drugs

  • SRF388

  • MTL-CEBPA

  • APX3330

  • Fostroxacitabine bralpamide

  • CDX-527

Liver Cancer Market Segmentation - Marketed Drugs

  • CYRAMZA (ramucirumab)

  • KEYTRUDA (pembrolizumab)

  • TECENTRIQ (atezolizumab)

  • JEMPERLI (dostarlimab)

  • OPDIVO (nivolumab)

  • YERVOY (ipilimumab)

Key Companies:

  • Shanghai Henlius Biotech

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Jiangsu Hengrui Medicine

  • Glaxo SmithKline

  • ZAI Lab

  • Beijing Immunochina Medical Science and Technology

  • MiNA Therapeutics

  • Abbisko Therapeutics

  • Medivir AB

  • Teclison

  • Genoscience

  • Eureka Therapeutics

Liver Cancer Market Segmentation -  By Type

  • Hepatocellular Carcinoma (HCC)

    • Conventional HCC

    • Fibrolamellar HCC

  • Intrahepatic Cholangiocarcinoma (ICC)

    • Peripheral ICC

    • Mass-Forming ICC

  • Hepatoblastoma

  • Angiosarcoma and Hemangiosarcoma

  • Others

    • Mixed Hepatocellular-Cholangiocarcinoma

    • Epithelioid Hemangioendothelioma

Liver Cancer Market Segmentation - By Administration Type

·  Oral

  • Capsules

  • Tablets

·  Injectable

  • Intravenous (IV)

  • Intramuscular (IM)

  • Intra-Arterial (IA)

·  Others

  • Transarterial Chemoembolization (TACE)

  • Transarterial Radioembolization (TARE)

What’s in It for You?

  • Gain insights into the most promising emerging and marketed therapies shaping the liver cancer landscape.

  • Identify strategic partnerships with key companies at the forefront of innovation.

  • Understand growth opportunities in immunotherapies, precision medicine, and targeted delivery systems.

  • Develop data-driven strategies to optimize investments in this growing market.

  • Stay ahead of competition with detailed analysis of market trends and therapeutic advancements.

Liver Cancer Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1. Liver Cancer Market - Executive Summary                                      

               1.1 Introduction                              

               1.2 Objectives                  

               1.3 Key Findings               

                              1.3.1 Market Size 2022 & 2032: By Key Country (10MM) 

                              1.3.2 Global Market Size 2022 & 2032: By Key Segment   

                              1.3.3 Key Investments & Startup Analysis              

               1.4 Research Methodology                          

                                            

2. Understanding the Disease                                   

               2.1 Disease Overview                    

               2.2 Classification                             

               2.3 Signs and Symptoms                              

               2.4 Risk Factors                

               2.5 Causes                        

               2.6 Disease Biology & Digital Innovations                              

               2.7 Stages & Staging System                      

               2.8 Diagnostic Algorithm                             

               2.9 Current Treatment Practices & Algorithm                      

               2.10 Current Standard of Care and Treatment Gaps                         

               2.11 Patient Demographics and Treatment Pathways                       

                                            

3. Guidelines                                    

                                            

4. Unmet Needs                                            

                                            

5. Epidemiology and Patient Population                                

               5.1 Epidemiology Key Findings                   

               5.2 Assumptions and Rationale: 10MM                 

               5.3 Epidemiology Scenario: 10MM                          

               5.4 U.S. Epidemiology Scenario                 

               5.5 EU-5 Epidemiology                  

                              5.5.1 U.K. Epidemiology Scenario             

                              5.5.2 Germany Epidemiology Scenario    

                              5.5.3 France Epidemiology Scenario         

                              5.5.4 Italy Epidemiology Scenario             

                              5.5.5 Spain Epidemiology Scenario           

               5.6 Japan Epidemiology Scenario                             

               5.7 China Epidemiology Scenario                             

               5.8 Australia Epidemiology Scenario                       

               5.9 India Epidemiology Scenario               

                                            

6. Real-world Data & Real-world Evidence                                           

                                            

7. Drug Development Landscape                                            

               7.1 Existing Key Drug Candidate Profiles/ Marketed Therapies                     

                              7.1.1 CYRAMZA (ramucirumabis)               

                                             7.1.1.1 Product Description

                                             7.1.1.2 Regulatory Milestones

                                             7.1.1.3 Other Developmental Activities

                                             7.1.1.4 Pivotal Clinical Trials

                                             7.1.1.5 Ongoing Current Pipeline Activity

                              7.1.2 KEYTRUDA (pembrolizumab)            

                                             7.1.2.1 Product Description

                                             7.1.2.2 Regulatory Milestones

                                             7.1.2.3 Other Developmental Activities

                                             7.1.2.4 Pivotal Clinical Trials

                                             7.1.2.5 Ongoing Current Pipeline Activity

                              7.1.3 TECENTRIQ (atezolizumab)

                                             7.1.3.1 Product Description

                                             7.1.3.2 Regulatory Milestones

                                             7.1.3.3 Other Developmental Activities

                                             7.1.3.4 Pivotal Clinical Trials

                                             7.1.3.5 Ongoing Current Pipeline Activity

                              7.1.4 JEMPERLI (dostarlimab)      

                                             7.1.4.1 Product Description

                                             7.1.4.2 Regulatory Milestones

                                             7.1.4.3 Other Developmental Activities

                                             7.1.4.4 Pivotal Clinical Trials

                                             7.1.4.5 Ongoing Current Pipeline Activity

                              7.1.5 OPDIVO (nivolumab)           

                                             7.1.5.1 Product Description

                                             7.1.5.2 Regulatory Milestones

                                             7.1.5.3 Other Developmental Activities

                                             7.1.5.4 Pivotal Clinical Trials

                                             7.1.5.5 Ongoing Current Pipeline Activity

               7.2 Competitive Analysis and Differentiation                        

               7.3 Overview of Similar/Competing Drugs in Clinical Trials                            

               7.4 Future Trends and Emerging Drugs                   

                              7.4.1 SRF388     

                                             7.4.1.1 Product Description

                                             7.4.1.2 Clinical Development

                                             7.4.1.3 Safety and Efficacy

                              7.4.2 MTL-CEBPA            

                                             7.4.2.1 Product Description

                                             7.4.2.2 Clinical Development

                                             7.4.2.3 Safety and Efficacy

                              7.4.3 APX3330   

                                             7.4.3.1 Product Description

                                             7.4.3.2 Clinical Development

                                             7.4.3.3 Safety and Efficacy

                                            

8. Regulatory Strategy and Potential Challenges                                

               8.1 Regulatory Pathways in Key Markets               

               8.2 Anticipated Regulatory Hurdles and Mitigation Strategies                      

               8.3 Case Studies in Oncology Drug Regulation                     

               8.4 Impact of Potential Changes to Regulatory Framework                            

                                            

9. Commercial Landscape                                          

               9.1 Market Size & Growth Rates               

               9.2 Key Approvals & Anticipated Loss of Exclusivity                          

               9.3 PESTLE & Porter’s Five Forces Analysis                           

               9.4 Market Shares, Positioning/Ranking                 

               9.5 Market Drivers                         

               9.6 Identification of Threats                       

               9.7 Digital Evolution in Commercialization                            

                                            

10. Market Segmentation                                           

               10.1 Market by Type                     

                              10.1.1 Hepatocellular Carcinoma              

                              10.1.2 Cholangio Carcinoma       

                              10.1.3 Hepatoblastoma  

                              10.1.4 Others    

               10.2 Market by Therapy Type                    

                              10.2.1 Targeted Therapy

                              10.2.2 Immunotherapy  

                              10.2.3 Chemotherapy     

                                            

11. Pricing, Reimbursement, and Access                              

               11.1 Competitive Pricing Analysis                            

               11.2 Reimbursement Landscape and Challenges                

               11.3 Strategies for Market Access and Equity                      

               11.4 Patient Spending/Expenditure Analysis                       

                                            

12. Future Trends, Disruptions, and Opportunities                                           

               12.1 Analysis of Emerging Trends                             

               12.2 Technological Impact                          

               12.3 Impact of Potential Market Disruptors                         

               12.4 Opportunities for Future Development and Expansion                          

               12.5 Considerations for Investment Opportunities                            

                                            

13. Global Market Dynamics                                     

               13.1 Regional Regulatory Disparities                       

               13.2 Cross-Border Partnership Strategies                             

               13.3 Global Supply Chain Dynamics                        

               13.4 Case Studies: Success and Failure in Global Markets               

               13.5 Strategies for Global Expansion and Localization                      

                                            

14. Company Profiles                                   

               14.1 Shanghai Henlius Biotech                  

               14.2 Boehringer Ingelheim                         

               14.3 Bristol-Myers Squibb                           

               14.4 Jiangsu Hengrui Medicine                  

               14.5 GlaxoSmithKline                     

               14.6 MiNA Therapeutics               

               14.7 Medivir AB               

               14.8 Takeda                      

               14.9 Imunon, Inc.                          

               14.10 Avant Immunotherapeutics, Inc.                  

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.